MEDIROM Healthcare Technologies Inc. American Depositary Share - MRM STOCK NEWS

SBC Medical Group Holdings (Nasdaq: SBC) has announced a strategic business alliance with MEDIROM Healthcare Technologies. The partnership combines SBC's 224 cosmetic treatment centers with MEDIROM's 300+ relaxation studios in Japan, jointly serving over 4 million loyalty program members.

The alliance aims to leverage their complementary customer bases - SBC's Shonan Beauty Clinic primarily serves women in their 20s-30s, while MEDIROM's Re.Ra.Ku focuses on male customers. An initial co-marketing campaign will run from November 15 to December 15, 2024, offering cross-promotional discounts across 130 Shonan Beauty Clinics and 230 Re.Ra.Ku stores.

MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) has announced a capital and business alliance between its subsidiary MEDIROM MOTHER Labs Inc. and Elematec (TOKYO PRIME: 2715), a member of the Toyota Tsusho group. Elematec has agreed to make a strategic investment in MEDIROM MOTHER Labs' Series A round at a pre-money valuation of 9 billion yen (approximately US$60,000,000).

Elematec is an electronics trading company with over 70 locations globally, providing commercial products in various fields including electronic devices, home appliances, and industrial equipment. The alliance aims to leverage Elematec's parts procurement, manufacturing services, and vast network of business partners to provide an additional distribution channel for MEDIROM's MOTHER Bracelet.

The MOTHER Bracelet offers advanced features for 24/7 health monitoring without the need for recharging, aligning with Elematec's customers' demand for new and feature-rich personal electronics.

MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) has announced its expansion into the rehabilitation industry through its newly established subsidiary, MEDIROM Rehab Solutions Inc. This subsidiary has acquired all ten cerebral infarction rehabilitation centers previously owned and operated by Y's, Inc. in Tokyo and other major Japanese cities.

Cerebral infarction rehabilitation is a comprehensive program designed to help stroke survivors, typically including physical therapy, occupational therapy, speech therapy, cognitive therapy, and emotional support. CEO Kouji Eguchi expressed enthusiasm about the expansion, highlighting the potential synergies between MEDIROM's existing wellness clinic operations, health-tech capabilities, and the newly acquired rehabilitation services.

MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) announced a capital and business alliance between its subsidiary MOTHER Labs and NFES Technologies. NFES Group will lead MOTHER Labs' Series A financing round, valuing the company at 9 billion yen pre-money. The alliance aims to promote the MOTHER Bracelet, a recharge-free smart health tracker, globally.

Key points:

• NFES Group will be the lead investor in MOTHER Labs' Series A round
• A distributorship agreement for MOTHER Bracelet and MOTHER Gateway has been concluded
• Products will be introduced to nursing care, transportation, and manufacturing industries
• Collaboration with Hyakkaten.com for general sales through department stores and e-commerce
• NFES Technologies established as the main distributor for MOTHER Bracelet products

MEDIROM Healthcare Technologies Inc. has announced that its subsidiary, MEDIROM Rehab Solutions Inc., has entered into an agreement to purchase a rehabilitation business from Y's, Inc., a Japanese The acquisition, finalized on July 10, 2024, involves 10 rehabilitation facilities around Tokyo specializing in care for cerebral infarction survivors.

This strategic move aligns with MEDIROM's diversified healthcare business model, aiming to provide a third option for patients beyond traditional medical and nursing care systems. The acquisition addresses the growing global stroke cases, expected to reach 3 million by 2025, and the limitations of Japan's 150-day health insurance coverage for rehabilitation.

MEDIROM's goal is to improve the quality of life for stroke survivors, including supporting working-age individuals in returning to work. This expansion into specialized rehabilitation services represents a significant step in MEDIROM's mission of promoting 'more health, more innovative' healthcare solutions.

MEDIROM Healthcare Technologies is set to acquire a 70% stake in Japan Gene Medicine , a leader in prenatal diagnosis and genetic testing, and has an option to acquire the remaining 30%. The acquisition process started on June 30, 2024, and is subject to certain conditions, including amending subcontracting agreements and securing funding. Japan Gene Medicine operates in an underutilized market in Japan, with only 7.2% of pregnant women utilizing such services in 2016, but significant growth potential due to demographic trends. The deal, valued at 2 billion yen, aims to capitalize on synergies with MEDIROM’s existing wellness services, expand its healthcare technology portfolio, and enhance its market position.

On June 20, 2024, MEDIROM Healthcare Technologies (NASDAQ: MRM) was one of four Nasdaq-listed Japanese companies participating in the NASDAQ JAPAN IR EVENT 2024 at Nasdaq's U.S. headquarters. The event aimed to elevate the presence of Japanese companies in the U.S. market. Over 120 investors and media attended, providing a platform for in-depth investor-company interactions. Koji Eguchi, CEO of MEDIROM, emphasized the event's success in fostering deeper understanding and communication between investors and Japanese companies.

The four presenting companies were MEDIROM Healthcare Technologies, SYLA Technologies, Earlyworks, and Lead Real Estate. The event is part of an ongoing initiative to regularly hold JAPAN IR events at Nasdaq headquarters to highlight Japanese companies' appeal worldwide.

Medirom Healthcare Technologies (NASDAQ: MRM) announced its financial results for fiscal year 2023, reporting net profit and positive adjusted EBITDA for the second consecutive year. Key contributors were its directly-operated wellness salons, the sale of 30 wellness salons, and growth in its Lav digital wellness app.

Revenues totaled $48.5 million, slightly down by 1.8% from 2022. The Relaxation Salon segment saw a modest revenue increase of 1.5%, but the Digital Preventative Healthcare segment saw a 48.1% decline. Operating expenses rose by 5.3%, leading to an operating loss of $2.8 million. Net income fell 22.8% to $816,000.

Despite the profit, adjusted EBITDA dropped by 19.5% to $2.2 million. Key factors were increased payroll, outsourcing costs, and interest expenses due to convertible bonds. Medirom launched full-scale operations of its REMONY Monitoring System and worked on expanding its B2B sales of healthtech platforms like MOTHER Bracelet and Gateway.

The NASDAQ JAPAN IR EVENT will take place at Nasdaq MarketSite in Times Square on June 20, 2024. MEDIROM Healthcare Technologies will participate, along with four other companies. The event aims to highlight the appeal of Japanese companies to the global market. Since MEDIROM's Nasdaq listing in December 2020, the number of Japanese companies on Nasdaq has grown to eight. The event is free with pre-registration required by June 7. It runs from 3:00pm to 9:00pm and includes presentations and an after-party.